These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32411298)

  • 1. Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials.
    Peng N; Liu W; Li Z; Wei J; Chen X; Wang W; Lin H
    Cardiovasc Ther; 2020; 2020():1042329. PubMed ID: 32411298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-Eluting Balloons Versus Everolimus-Eluting Stents for In-Stent Restenosis: A Meta-Analysis of Randomized Trials.
    Elgendy IY; Mahmoud AN; Elgendy AY; Mojadidi MK; Elbadawi A; Eshtehardi P; Pérez-Vizcayno MJ; Wayangankar SA; Jneid H; David Anderson R; Alfonso F
    Cardiovasc Revasc Med; 2019 Jul; 20(7):612-618. PubMed ID: 30126824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3-Year Clinical Follow-Up of the RIBS IV Clinical Trial: A Prospective Randomized Study of Drug-Eluting Balloons Versus Everolimus-Eluting Stents in Patients With In-Stent Restenosis in Coronary Arteries Previously Treated With Drug-Eluting Stents.
    Alfonso F; Pérez-Vizcayno MJ; Cuesta J; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Cequier A; Velázquez M; Moreno R; Mainar V; Domínguez A; Moris C; Molina E; Rivero F; Jiménez-Quevedo P; Gonzalo N; Fernández-Pérez C;
    JACC Cardiovasc Interv; 2018 May; 11(10):981-991. PubMed ID: 29798776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Results of Everolimus-Eluting Stents Versus Drug-Eluting Balloons in Patients With Bare-Metal In-Stent Restenosis: 3-Year Follow-Up of the RIBS V Clinical Trial.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; Otaegui I; Masotti M; Zueco J; Veláquez M; Sanchís J; García-Touchard A; Lázaro-García R; Moreu J; Bethencourt A; Cuesta J; Rivero F; Cárdenas A; Gonzalo N; Jiménez-Quevedo P; Fernández C;
    JACC Cardiovasc Interv; 2016 Jun; 9(12):1246-1255. PubMed ID: 27339840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel-eluting balloon versus everolimus-eluting stent in patients with diabetes mellitus and in-stent restenosis: Insights from the randomized DARE trial.
    Claessen BE; Henriques JPS; Vendrik J; Boerlage-van Dijk K; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; Piek JJ; Baan J
    Catheter Cardiovasc Interv; 2019 Feb; 93(2):216-221. PubMed ID: 30232824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-generation drug-eluting stents versus drug-coated balloons for the treatment of coronary in-stent restenosis: A systematic review and meta-analysis.
    Kokkinidis DG; Prouse AF; Avner SJ; Lee JM; Waldo SW; Armstrong EJ
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):285-299. PubMed ID: 29024274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes after treatment of bare-metal stent restenosis with paclitaxel-coated balloon catheters or everolimus-eluting stents: 3-year follow-up of the TIS clinical study.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):E416-E424. PubMed ID: 30019843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis.
    Pleva L; Kukla P; Zapletalova J; Hlinomaz O
    BMC Cardiovasc Disord; 2017 Jun; 17(1):168. PubMed ID: 28651572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels.
    Giannini F; Latib A; Ancona MB; Costopoulos C; Ruparelia N; Menozzi A; Castriota F; Micari A; Cremonesi A; De Felice F; Marchese A; Tespili M; Presbitero P; Sgueglia GA; Buffoli F; Tamburino C; Varbella F; Colombo A
    Catheter Cardiovasc Interv; 2017 Sep; 90(3):380-386. PubMed ID: 28109036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison between drug-coated balloon angioplasty and second-generation drug-eluting stent placement for the treatment of in-stent restenosis after drug-eluting stent implantation.
    Kang IS; Shehata I; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Heart Vessels; 2016 Sep; 31(9):1405-11. PubMed ID: 26337620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term clinical safety and efficacy of drug-coated balloon in the treatment of in-stent restenosis: A meta-analysis and systematic review.
    Xi Y; Chen J; Bi Y; Xie S; Liao T; Zhang Y; Kislauskis E; Wu T; Laham R; Xiao J
    Catheter Cardiovasc Interv; 2020 Aug; 96(2):E129-E141. PubMed ID: 31714010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.
    Baan J; Claessen BE; Dijk KB; Vendrik J; van der Schaaf RJ; Meuwissen M; van Royen N; Gosselink ATM; van Wely MH; Dirkali A; Arkenbout EK; de Winter RJ; Koch KT; Sjauw KD; Beijk MA; Vis MM; Wykrzykowska JJ; Piek JJ; Tijssen JGP; Henriques JPS
    JACC Cardiovasc Interv; 2018 Feb; 11(3):275-283. PubMed ID: 29413242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiographic patterns of drug-eluting stent restenosis after treatment with drug-coated balloon versus balloon angioplasty: Late lumen loss subgroup analyses of the PEPCAD-DES study.
    Rittger H; Wöhrle J; Brachmann J; Hohenforst-Schmidt W; Schlundt C; Lonke S; von Cranach M; Markovic S; Achenbach S; Waliszewski M
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):529-534. PubMed ID: 26893095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year follow-up of a propensity score matching comparison (the BIORESOLVE-ISR Study).
    Moscarella E; Tanaka A; Ielasi A; Cortese B; Coscarelli S; De Angelis MC; Piraino D; Latib A; Grigis G; Bianchi R; Buccheri D; Calabrò P; Tespili M; Silva Orrego P; Colombo A; Varricchio A
    Catheter Cardiovasc Interv; 2018 Oct; 92(4):668-677. PubMed ID: 29356269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study.
    Cuesta J; Pérez-Vizcayno MJ; García Del Blanco B; Bosa F; Pérez de Prado A; Rumoroso JR; Romaguera R; Gutiérrez H; García Touchard A; López-Mínguez JR; Trillo R; de la Torre Hernández JM; Moreno R; Velázquez M; Moris C; Kockar MJ; Jiménez-Quevedo P; Bastante T; Del Val D; Rivero F; Alfonso F
    JACC Cardiovasc Interv; 2024 Aug; 17(15):1825-1836. PubMed ID: 39142758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiography and Optical Coherence Tomography Assessment of the Drug-Coated Balloon ESSENTIAL for the Treatment of In-Stent Restenosis.
    de la Torre Hernández JM; Garcia Camarero T; Lozano Ruiz-Poveda F; Urbano-Carrillo CA; Sánchez Pérez I; Cano-García M; Saez R; Andrés Morist A; Molina E; Pinar E; Torres A; Lezcano EJ; Gutierrez H; Arnold RJ; Zueco J
    Cardiovasc Revasc Med; 2020 Apr; 21(4):508-513. PubMed ID: 31401071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of drug-coated balloon angioplasty in early versus late occurring drug-eluting stent restenosis: A pooled analysis from the randomized ISAR DESIRE 3 and DESIRE 4 trials.
    Koch T; Cassese S; Xhepa E; Mayer K; Tölg R; Hoppmann P; Laugwitz KL; Byrne RA; Kastrati A; Kufner S
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):1008-1015. PubMed ID: 31789486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neointimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents: A Randomized Controlled Trial.
    Kufner S; Joner M; Schneider S; Tölg R; Zrenner B; Repp J; Starkmann A; Xhepa E; Ibrahim T; Cassese S; Fusaro M; Ott I; Hengstenberg C; Schunkert H; Abdel-Wahab M; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2017 Jul; 10(13):1332-1340. PubMed ID: 28683939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.